Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 8/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | CCR3 | P51677 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL614815 | 0.92 | SLC6A9 (0.39) | SLC6A9KCNH2MAPK1NPC1RORC | |
| SCHEMBL616508 | 0.92 | SLC6A9 (0.38) | SLC6A9KCNH2CCR3ALDH1A1POLB | |
| SCHEMBL616115 | 0.91 | SLC6A9 (0.44) | SLC6A9KCNH2CCR3KMT2AALDH1A1 | |
| SCHEMBL615535 | 0.89 | GALR3 (0.41) | SLC6A9KCNH2KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL617356 | 0.88 | SCN9A (0.36) | SLC6A9MAPK1NPC1RORCCCR3 | |
| SCHEMBL614760 | 0.88 | SLC6A9 (0.44) | SLC6A9KCNH2CCR3L3MBTL1ALDH1A1 | |
| SCHEMBL604552 | 0.87 | SLC6A9 (0.46) | SLC6A9KCNH2MAPK1RORCKMT2A | |
| SCHEMBL617452 | 0.86 | SLC6A9 (0.38) | SLC6A9KCNH2RORCKMT2AMEN1 | |
| SCHEMBL614203 | 0.86 | SLC6A9 (0.46) | SLC6A9KCNH2SCN9A | |
| SCHEMBL604682 | 0.84 | SLC6A9 (0.44) | SLC6A9KCNH2RORCKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | claimed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | claimed |
| EP-2709987-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | Abbott GmbH & Co. KG (DE) | 2014-03-26 | — | — | EP | claimed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | claimed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | claimed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | claimed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-9051280-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | AbbVie Deutschland GmbH & Co. KG (DE) | 2015-06-09 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-8883839-B2 | Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy | ABBOTT LABORATORIES (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-11-22 | — | — | US | disclosed |
| WO-2012020133-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT GMBH & CO. KG (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | ABBOTT LABORATORIES (US) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040947-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885KCNH2 1552/4885MAPK1 1263/4885 |
| US-20120295881-A1 | TETRALINE AND INDANE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THEIR USE IN THERAPY | SLC10A1, SUGT1, SLC10A2 | SLC6A9 42/4885KCNH2 1552/4885MAPK1 1263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.